



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/72, C09K 3/30	A1	(11) International Publication Number: WO 92/22287 (43) International Publication Date: 23 December 1992 (23.12.92)
(21) International Application Number: PCT/US92/04618 (22) International Filing Date: 8 June 1992 (08.06.92) (30) Priority data: 712,789 10 June 1991 (10.06.91) US (60) Parent Application or Grant (63) Related by Continuation US 712,789 (CIP) Filed on 10 June 1991 (10.06.91) (71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). (72) Inventors; and (75) Inventors/Applicants (for US only) : FASSBERG, Julianne [US/US]; 175 W. 12th Street, New York, NY 10011 (US). SEQUEIRA, Joel, A. [US/US]; 18 Stuyvesant Oval, New York, NY 10009 (US). CHAUDRY, Imtiaz, A. [US/US]; 18 Rose Avenue, North Caldwell, NJ 07006 (US). KOPCHA, Michael [US/US]; 141 Wycoff Way West, East Brunswick, NJ 08816 (US).		(74) Agents: FRANKS, Robert, A. et al.; Schering-Plough Corporation, One Giralda Farms, Madison, NJ 07940-1000 (US). (81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report.</i>
(54) Title: NON-CHLOROFLUOROCARBON AEROSOL FORMULATIONS (57) Abstract Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration are described. The formulations comprise 1,1,1,2 tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations also are described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

5

NON-CHLOROFLUOROCARBON AEROSOL FORMULATIONS10 **INTRODUCTION TO THE INVENTION**

The present invention is directed at aerosol formulations which are substantially free of chlorofluorocarbons (CFC's). More specifically, the present invention is directed at formulations
15 substantially free of CFC's and having particular utility in medicinal applications, especially in metered dose pressurized inhalators (MDI's).

Metered dose inhalators have proven to be an effective method for delivering medicaments orally and nasally. They have been used extensively for delivering bronchodilating and steroidal
20 compounds to asthmatics and may also be useful for delivering other compounds such as pentamidine and non-bronchodilator anti-inflammatory drugs. The rapid onset of activity of compounds administered in this manner and the absence of any significant side effects have resulted in a large number of compounds being formulated
25 for administration via this route. Typically, the drug is delivered to the patient by a propellant system generally comprising one or more propellants which have the appropriate vapor pressure and which are suitable for oral or nasal administration. The more preferred propellant systems typically comprise propellant 11, propellant 12, propellant 114 or mixtures thereof. Often the vapor pressure of the propellant systems
30 is adjusted by admixing a liquid excipient with the propellant.

However, propellants 11, 12 and 114 belong to a class of compounds known as chlorofluorocarbons, which have been linked to the depletion of ozone in the atmosphere. It has been postulated that
35 ozone blocks certain harmful UV rays and that a decrease in the atmospheric ozone content will result in an increase in the incidence of

- 2 -

skin cancer. In the 1970's certain steps were taken to reduce the CFC emissions from aerosols. Other propellants, such as hydrocarbons, were used, or the product was delivered in a different manner. Because CFC usage in medicinal applications is relatively low i.e. less than 1% of total CFC emissions, and because of the health benefits associated with metered dose inhalators, steps were not taken at that time to restrict the use of CFC propellants in metered dose inhalators.

However, continuing and more sophisticated ozone measurements have indicated that the earlier restrictions in CFC usage were insufficient and that additional, significant steps should be taken to drastically reduce CFC emissions. Recently, recommendations have been made that CFC production be virtually discontinued by the end of this century. As a result, it may not be possible to continue to use CFC propellants in the intermediate and long term. While some efforts have been made to use non-pressurized metered dose inhalators, many of these devices have not been completely successful. Many do not deliver uniform doses, are mechanically complex, do not provide the 100-200 doses per unit of current aerosol containers, are difficult for individuals to utilize, are bulky and/or cumbersome for the patients to use, particularly when they have an acute need for the medication.

As a result, there is a need for aerosol formulations substantially free of CFC's. Non-CFC propellants must meet several criteria for pressurized metered dose inhalators. They must be non-toxic, stable and non-reactive with the medicament and the other major components in the valve/actuator. One propellant which has been found to be suitable is $\text{CF}_3\text{-CH}_2\text{F}$, also known as Freon 134a, HFA 134a, HFC 134a or 1,1,1,2 tetrafluoroethane. However, the physical properties, i.e. vapor pressure, polarity, solubility, density and viscosity of HFC 134a differ from those of commonly used propellants. Propellant HFC 134a has a vapor pressure of 5.84×10^5 newton/meter² absolute (84.7 psia), which is too high for use in metered dose inhalators. In addition, commonly used surfactants may be insoluble in HFC 134a. Moreover, where the medicament is to be delivered as a solution, the medicament may not be readily soluble in this propellant. The density and polarity difference between HFC 134a and the previously used CFC propellant

- 3 -

may result in a different delivery of the medicament when HFC 134a replaces a CFC propellant. The medicament may cream, settle or agglomerate in the non-CFC propellant even though this did not occur in the CFC propellant.

5 The use of HFA 134a previously has been disclosed for use in medicinal inhalators. European Patent Publication No. 0 372 777 is directed at medicinal aerosol formulations incorporating Freon 134a and an adjuvant having a higher polarity than the propellant. This publication lists several possible adjuvants and surfactants for use in
10 combination with the propellant and the medicament.

 International patent application No. WO 91/04011 discloses the combination of 1,1,1,2 tetrafluoroethane and a powdered medicament pre-coated with a non-perfluorinated surfactant prior to dispersing the powdered medicament in the propellant. Pages 6-7 of
15 the publication list suitable surfactants for use with the propellant. A perfluorinated adjuvant optionally could be added. However, the pre-coating of the medicament may not be advantageous, since it adds an additional, complex step to the manufacturing process.

Research Disclosure No. 30161, May 1989 discloses that
20 non-CFC propellants such as fluorohydrocarbons may be used in pressurized medicaments delivered directly to the lungs e.g. bronchodilators.

 U.S. Patent No. 4,174,295 discloses the combination of HFC 134a with various chlorofluorocarbons and optionally a saturated
25 hydrocarbon.

 U.S. Patent No. 2,885,427 discloses the use of HFC-134a as an aerosol propellant.

 U.S. Patent No. 3,261,748 discloses the use of HFC-134a for anesthesia.

30 U.S. Patent Nos. 4,129,603, 4,311,863, 4,851,595 and European Publication No. 379,793 also disclose the use of HFC-134a as an aerosol propellant.

 However, the specific combinations noted above may not provide the desired solubility, stability, low toxicity, exact dosage, correct

- 4 -

particle size (if suspension) and/or compatibility with commonly used valves assemblies of metered dose inhalers.

SUMMARY OF THE INVENTION

5 The present invention is directed at non-toxic formulations substantially free of CFC's, having improved stability and compatibility with the medicament and valve components and which are relatively easily manufactured.

10 The present invention also is directed at formulations which may be utilized in present aerosol filling equipment with only relatively minor modifications and without pre-coating the medicament.

The invention includes an aerosol formulation comprising:

- 15 A. an effective amount of medicament; and
 B. 1,1,1,2 tetrafluoroethane.

20 The formulation optionally may further comprise an excipient preferably selected from the group consisting of:

- propylene glycol diesters of medium chain
 fatty acids;
 triglyceride esters of medium chain fatty
 acids;
25 perfluorodimethylcyclobutane;
 perfluorocyclobutane;
 polyethylene glycol;
 menthol;
 lauroglycol;
30 diethylene glycol monoethylether;
 polyglycolized glycerides of medium chain
 fatty acids;
 alcohols;
 eucalyptus oil;
35 short chain fatty acids;
 and combinations thereof.

- 5 -

The formulation optionally may further comprise a surfactant. The surfactant preferably is selected from the group consisting of:

- 5 oleic acid;
 sorbitan trioleate;
 cetyl pyridinium chloride;
 soya lecithin;
 polyoxyethylene(20) sorbitan monolaurate;
 polyoxyethylene(20) sorbitan monostearate;
10 polyoxyethylene(20) sorbitan monooleate;
 polyoxypropylene-polyoxyethylene block
 copolymers;
 polyoxyethylene (10).stearyl ether;
 polyoxyethylene (2) oleyl ether;
15 polyoxypropylene-polyoxyethylene-
 ethylenediamine block copolymers;
 castor oil ethoxylate; and combinations
 thereof.

- 20 The preferred liquid excipients are diethylene glycol monethyether, propylene glycol diesters of medium chain fatty acids, perfluorodimethylcyclobutane and polyethylene glycol.

- The preferred surfactants are oleic acid; sorbitan trioleate, cetylpyridinium chloride; polyoxyethylene (20) sorbitan monolaurate;
25 polyoxypropylene-polyoxyethylene block copolymers; soya lecithin; and polyoxypropylene-polyoxyethylene-ethylenediamine block copolymers; with oleic acid being particularly preferred.

- The invention is of particular utility where the medicament is albuterol, mometasone furoate or beclomethasone dipropionate, and
30 salts and clathrates thereof.

A formulation range comprises:

- | | | | |
|---------------------|----------------------------|----|---------------|
| 35 A. | 1,1,1,2 tetrafluoroethane | 25 | - 99.99 wt % |
| | B. medicament | | 0.01 - 1 wt % |
| | C. excipient | 0 | - 75 wt % |
| | D. surfactant (if present) | 0 | - 3 wt % |

- 6 -

The present invention also is directed at a method of treating asthma in mammals comprising administering to a mammal in need of such treatment an effective amount of aerosol formulation

5 comprising:

A. a medicament selected from the group comprising albuterol, mometasone furoate, beclomethasone dipropionate, and salts and clathrates thereof;

B. 1,1,1,2 tetrafluoroethane; and

10 C. optionally an excipient, preferably selected from the group consisting of:

propylene glycol diesters of medium chain fatty acids;

15 triglyceride esters of medium chain fatty acids;

perfluorodimethylcyclobutane;

perfluorocyclobutane;

polyethylene glycol;

menthol;

20 lauroglycol;

diethylene glycol monoethylether;

polyglycolized glycerides of medium chain fatty acids;

alcohols;

25 short chain fatty acids;

eucalyptus oil; and combinations thereof.

A surfactant optionally is present. The surfactant preferably is selected from the group consisting of:

30

oleic acid;

sorbitan trioleate;

cetyl pyridinium chloride;

soya lecithin;

35 polyoxyethylene (20) sorbitan monolaurate;

- 7 -

polyoxyethylene (20) sorbitan monostearate;
polyoxypropylene-polyoxyethylene block
copolymers;
polyoxyethylene (10) stearyl ether
polyoxyethylene (2) oleyl ether
polyoxyethylene-polyoxypropylene-ethylene
diamine block copolymers
castor oil ethoxylate; and combinations
thereof.

DETAILED DESCRIPTION OF THE INVENTION

The formulations of the present invention all utilize propellant 134a in combination with the medicament, optionally a liquid excipient and optionally a surfactant. The excipient facilitates the compatibility of the medicament with the propellant and also lowers the discharge pressure to an acceptable range i.e. about $2.76 - 5.52 \times 10^5$ newton/meter² absolute (40 to 80 psia), preferably $3.45 - 4.83 \times 10^5$ newton/meter² absolute (50 to 70 psia). The excipient chosen must be non-reactive with the medicament, relatively non-toxic, and should have a vapor pressure below about 3.45×10^5 newton/meter² absolute (50 psia). As used hereinafter the term "medium chain fatty acids" refers to chains of alkyl groups terminating in a -COOH group and having 6-12 carbon atoms, preferably 8-10 carbon atoms. The term "short chain fatty acids" refers to chains of alkyl groups terminating in a -COOH group and having 4-8 carbon atoms. The term "alcohol" includes C₁-C₃ alcohols, such as methanol, ethanol and isopropanol. Among the preferred excipients are:

propylene glycol diesters of medium chain fatty acids available under the tradename Miglyol 840 (from Hüls America, Inc. Piscataway, N.J.);
triglyceride esters of medium chain fatty acids available under the tradename Miglyol 812 (from Hüls);
perfluorodimethylcyclobutane available under the tradename Vertrel 245 (from E.I DuPont de Nemours and Co. Inc. Wilmington, Delaware);

- 8 -

- perfluorocyclobutane available under the tradename octafluoro cyclobutane (from PCR Gainsville, Florida);
polyethylene glycol available under the tradename PEG 400 (from BASF Parsippany, N.J.);
5 menthol (from Pluess-Stauffer International Stanford, Connecticut);
propylene glycol monolaurate available under the tradename lauroglycol (from Gattefossé Elmsford, N.Y.);
diethylene glycol monoethylether available under the
10 tradename Transcutol (from Gattefossé);
polyglycolized glyceride of medium chain fatty acids available under the tradename Labrafac Hydro WL 1219 (from Gattefossé);
alcohols, such as ethanol, methanol and isopropanol;
15 eucalyptus oil (available from Pluess-Stauffer International); and mixtures thereof.
- A surfactant optionally may be added to lower the surface and interfacial tension between the medicament and the propellant. Where the medicament, propellant and excipient are to form a
20 suspension, a surfactant may or may not be required. Where the medicament, propellant and excipient are to form a solution, a surfactant may or may not be necessary, depending in part on the solubility of the particular medicament and excipient. The surfactant may be any
25 suitable, non-toxic compound which is non-reactive with the medicament and which substantially reduces the surface tension between the medicament, the excipient and the propellant and/or acts as a valve lubricant. Among the preferred surfactants are:
oleic acid available under the tradename oleic acid NF6321 (from Henkel Corp. Emery Group, Cincinnati, Ohio);
30 cetylpyridinium chloride (from Arrow Chemical, Inc. Westwood, N.J.);
soya lecithin available under the tradename Epikuron 200 (from Lucas Meyer Decatur, Illinois);
polyoxyethylene (10) stearyl ether available under the
35 tradename Briji 76 (from ICI);

- 9 -

polyoxyethylene (2) oleyl ether available under the tradename Brij 92 (from ICI);

polyoxyethylene-polypropylene-ethylenediamine block copolymer available under the tradename Tetronic 150 R1 (from BASF);

5 polyoxyethylene(20) sorbitan monolaurate available under the tradename Tween 20 (from ICI Specialty Chemicals, Wilmington, Delaware);

polyoxyethylene(20) sorbitan monostearate available under the tradename Tween 60 (from ICI);

10 polyoxyethylene(20) sorbitan monooleate available under the tradename Tween 80 (from ICI);

polyoxypropylene-polyoxyethylene block copolymers available under the tradenames Pluronic L-92, Pluronic L-121 and Pluronic F 68 (from BASF);

15 castor oil ethoxylate available under the tradename Alkasurf CO-40 (from Rhone-Poulenc Mississauga Ontario, Canada); and mixtures thereof.

The medicaments of the present invention may include any pharmaceutically active compounds which are to be delivered by oral
20 inhalation or nasally. Typical classes of compounds include bronchodilators, anti-inflammatory compounds, antihistamines, antiallergics, analgesics, antitussives, anti-anginal medications, steroids, corticosteroids, vasoconstrictors and antibiotics. Specific compounds within these classes of compounds are albuterol,
25 mometasone furoate, beclomethasone dipropionate, isoproterenol, heparin, terbutaline, rimiterol, perbuterol, disodium cromoglycate, isoprenaline, adrenaline, pentamidine and ipratropium bromide. These compounds may be utilized either as the free base, as a salt, or as a clathrate depending upon the stability and solubility of the active
30 compound in the specific formulation. Where clathrates are utilized, P-11 and hexane clathrates are particularly preferred.

Where the active compound forms a suspension, the particle size should be relatively uniform, with substantially all the particles preferably ranging between about 0.1-25 microns, preferably
35 0.5-10 microns, more preferably 1-5 microns. Particles larger than 25

- 10 -

microns may be held up in the oropharyngeal cavity, while particles smaller than about 0.5 micron preferably are not utilized, since they would be more likely to be exhaled and, therefore, not reach the lungs of the patient.

5 The formulations of the present invention may be filled into the aerosol containers using conventional filling equipment. Since propellant 134a may not be compatible with all elastomeric compounds currently utilized in present aerosol valve assemblies, it may be necessary to substitute other materials, such as white buna rubber, or to
10 utilize excipients and optionally surfactants which mitigate the adverse effects of propellant 134a on the valve components. One may optionally use an actuator device with a spacer to reduce force of the spray from an MDI.

15 To assure uniform dispersion of the active ingredient, the formulations typically will include the following components:

	<u>Range (wt %)</u>	<u>Preferred Range (wt%)</u>	<u>Most Preferred Range (wt%)</u>
Medicament	0.01 - 1	0.03 - 0.7	0.05 - 0.5
Propellant	25 - 99.99	50 - 99.97	50 - 99.95
Excipient(s)	0 - 75	0 - 50	0 - 50
Surfactant(s)	0 - 3	0 - 2	0 - 1

20 Depending on the particular application, the container may be charged with a predetermined quantity of formulation for single or multiple dosing. Typically, the container is sized for multiple-dosing, and, therefore, it is very important that the formulation delivered is substantially uniform for each dosing. For example, where the formulation is for bronchodilation, the container typically is charged with a sufficient quantity of the formulation for 200 charges.

25 Suitable suspensions may be screened in part by observing several physical properties of the formulation, i.e. the rate of particle agglomeration, the size of the agglomerates and the rate of particulate creaming/settling and comparing these to an acceptable standard. Suitable solutions may be screened by observing the

- 11 -

solubility of the medicament over the entire recommended storage temperature range.

Suspensions of the present invention preferably may be prepared by either the pressure filling or cold filling procedures well-known in the art.

For metered dose inhalators, suspensions may be particularly preferred for efficacy and stability considerations.

Those skilled in the art may choose to add one or more preservative, buffer, antioxidant, sweetener and/or flavors or other taste masking agents depending upon the characteristics of the formulation.

Examples I - XXXII below further describe representative formulations of the present invention, some examples showing alternative formulations "A" and "B".

15

Example I

<u>Component</u>	<u>wt %</u>
Albuterol	0.1
Vetrel 245	9.9
HFC-134a	90.0

Example II

<u>Component</u>	<u>wt %</u>
Albuterol	0.5
Vetrel 245	49.9
HFC-134a	49.6

- 12 -

Example III

<u>Component</u>	<u>wt %</u>
Albuterol	0.1
Oleic Acid	0.01
Miglyol 840	9.0
HFC 134a	90.89

5

Example IV

<u>Component</u>	<u>wt %</u>
Albuterol	0.1
Tetronic 150 R1	0.1
Miglyol 840	9.8
HFC 134a	90.0

Example V

<u>Component</u>	<u>wt %</u>
Albuterol	0.1
Pluronic L-121	0.1
Miglyol 840	9.8
HFC 134a	90.0

- 13 -

Example VI

<u>Component</u>	<u>wt %</u>
Albuterol	0.1
Oleic acid	0.2
Transcutol	18.0
HFC 134a	81.7

5

Example VII

<u>Component</u>	<u>A</u> <u>wt %</u>	<u>B</u> <u>wt %</u>
Albuterol	0.10	0.10
Oleic acid	0.01	0.01
Ethanol	30.00	15.00
HFC 134a	69.89	84.89

Example VIII

<u>Component</u>	<u>A</u> <u>wt %</u>	<u>B</u> <u>wt %</u>
Albuterol sulfate	0.10	0.10
Oleic acid	0.01	0.01
Ethanol	30.00	15.00
HFC-134a	69.89	84.89

- 14 -

Example IX

<u>Component</u>	<u>wt %</u>
Albuterol	0.1
Vetrel 245	17.0
Miglyol 840	9
HFC-134a	73.9

5

Example X

<u>Component</u>	<u>wt %</u>
Albuterol	0.10
Oleic acid	0.01
Ethanol	10.00
Vertrel 245	9.90
HFC 134a	79.99

Example XI

<u>Component</u>	<u>wt %</u>
Albuterol	0.1
Pluronic L-121	0.4
Vertrel 245	16.6
Miglyol 840	9
HFC-134a	73.9

- 15 -

Example XII

<u>Component</u>	<u>wt %</u>
Albuterol	0.10
Pluronic L-121	0.90
Oleic acid	0.01
Miglyol 840	9.00
HFC 134a	89.99

5

Example XIII

<u>Component</u>	<u>wt %</u>
Albuterol	0.10
Tetronic 150 R1	0.10
Oleic Acid	0.01
Miglyol 840	9.80
HFC-134a	89.99

Example XIV

<u>Component</u>	<u>A</u> <u>wt %</u>	<u>B</u> <u>wt%</u>
Mometasone furoate	0.10	0.10
Oleic acid	0.01	0.01
Ethanol	30.00	15.00
HFC-134a	69.89	84.89

10

- 16 -

Example XV

<u>Component</u>	<u>wt %</u>
Mometasone furoate	0.1
Oleic acid	0.2
Transcutol	18.0
HFC-134a	81.7

Example XVI

5

<u>Component</u>	<u>wt %</u>
Mometasone furoate	0.1
Tween 20	0.1
Miglyol 840	9.8
HFC-134a	90.0

Example XVII

<u>Component</u>	<u>wt%</u>
Mometasone furoate	0.1
Pluronic L-121	0.4
Miglyol 840	9.0
HFC-13a	90.5

10

Example XVIII

<u>Component</u>	<u>wt%</u>
Mometasone furoate	0.1
Tetronic 150 R1	0.1
Miglyol 840	9.8
HFC-134a	90

- 17 -

Example XIX

<u>Component</u>	<u>wt %</u>
Beclomethasone dipropionate	0.1
Oleic acid	0.01
Ethanol	5
HFC 134a	94.89

Example XX

5

<u>Component</u>	<u>wt %</u>
Beclomethasone dipropionate P-11 clathrate	0.1
Oleic acid	.01
Miglyol 840	1.5
HFC-134a	98.39

Example XXI

<u>Component</u>	<u>wt %</u>
Beclomethasone dipropionate hexane clathrate	0.1
Pluronic L121	.01
Miglyol 840	1.5
HFC-134a	98.3

10

Example XXII

<u>Component</u>	<u>wt%</u>
Mometasone Furoate	0.1
HFC-134a	99.9

- 18 -

Example XXIII

<u>Component</u>	<u>wt%</u>
Beclomethasone Dipropionate P-11 Clathrate	0.1
HFC-134a	99.9

Example XXIV

5

<u>Component</u>	<u>wt%</u>
Mometasone Furoate	0.1
Tween 20	0.01
HFC-134a	99.89

Example XXV

<u>Component</u>	<u>wt%</u>
Beclomethasone Dipropionate P-11 Clathrate	0.1
Tween 20	0.01
HFC-134a	99.89

10

Example XXVI

<u>Component</u>	<u>wt%</u>
Mometasone furoate	0.1
Tween 20	0.01
Oleic Acid	0.0005
HFC-134a	99.8895

- 19 -

Example XXVII

<u>Component</u>	<u>wt%</u>
Mometasone Furoate	0.1
Miglyol 840	9
Oleic Acid	0.005
Tetronic 150 R1	0.01
HFC-134a	90.885

Example XXVIII

5

<u>Component</u>	<u>wt%</u>
Beclomethasone Dipropionate P-11 Clathrate	0.1
Miglyol 840	3
Oleic Acid	0.005
Pluronic L 121	0.01
HFC-134a	96.885

Example XXIX

<u>Component</u>	<u>wt %</u>
Beclomethasone dipropionate	0.1
Oleic acid	0.2
Transcutol	5
HFC-134a	94.7

10

Example XXX

<u>Component</u>	<u>wt %</u>
Beclomethasone dipropionate P-11 Clathrate	0.1
Pluronic L-121	0.1
Miglyol 840	1.5
HFC-134a	98.7

- 20 -

Example XXXI

<u>Component</u>	<u>wt%</u>
Beclomethasone dipropionate	0.1
PEG 400	5
HFC-134a	94.9

5

Example XXXII

<u>Component</u>	<u>wt%</u>
Beclomethasone Dipropionate P-11 Clathrate	0.1
Miglyol 840	1.5
HFC-134a	94.9

While the examples above have been directed at albuterol, albuterol sulfate, mometasone furoate, beclomethasone dipropionate and beclomethasone dipropionate clathrates, it is contemplated that other orally or nasally administered medicaments could be utilized. Similarly, it is contemplated that excipients and surfactants other than those exemplified may be utilized.

The descriptions of the foregoing embodiments of the invention have been presented for purpose of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

- 21 -

What is claimed is:

1. An aerosol formulation consisting essentially of:
 - A. an effective amount of a medicament;
 - 5 B. 1,1,1,2 tetrafluoroethane; and
optionally, one or more components selected from at least one of the following:
excipients;
surfactants; and
10 additives which are:
preservatives;
buffers;
antioxidants;
sweeteners; and
15 taste masking agents.
2. The formulation of claim 1 wherein the excipient is selected from the group consisting of:
propylene glycol diesters of medium chain fatty acids;
20 triglyceride esters of medium chain fatty acids;
perfluorodimethylcyclobutane;
perfluorocyclobutane;
polyethylene glycol;
menthol;
25 lauroglycol;
diethylglycol monoethylether;
polyglycolized glycerides of medium chain fatty acids;
alcohols;
short chain fatty acids;
30 eucalyptus oil; and combinations thereof.
3. The formulation of claim 1 wherein the surfactant is selected from the group consisting of:
oleic acid;
35 sorbitan trioleate;

- 22 -

5 cetyl pyridinium chloride;
soya lecithin;
polyoxyethylene (20) sorbitan monolaurate;
polyoxyethylene(20) sorbitan monostearate;
polyoxyethylene(20) sorbitan monooleate;
polyoxypropylene-polyoxyethylene block copolymers;
polyoxyethylene (10) stearyl ether;
polyoxyethylene (2) oleyl ether;
polyoxyethylene-polyoxypropylene-ethylenediamine block
10 copolymers;
castor oil ethoxylate; and combinations thereof.

4. The formulation of claim 1 wherein the medicament is selected
from the group consisting of: albuterol, mometasone furoate,
15 beclomethasone dipropionate, isoproterenol, heparin, terbutaline,
rimiterol, perbuterol, disodium cromoglycate, isoprenaline, adrenaline,
pentamidine, ipratropium bromide, and salts and clathrates thereof.

5. The formulation of claim 4 wherein the medicament is selected
20 from the group consisting of:
albuterol, albuterol sulfate beclomethasone dipropionate,
beclomethasone dipropionate clathrates and mometasone furoate.

6. The formulation of claim 5 which is substantially free of
25 chlorofluorocarbons.

7. The formulation of claim 5 containing an excipient selected from
the group consisting of diethylene glycol monoethyl ether, propylene
glycol diesters of medium chain fatty acids,
30 perfluorodimethylcyclobutane and polyethylene glycol.

8. The formulation of claim 7 containing a surfactant selected from
the group consisting of: oleic acid, sorbitan trioleate, cetylpyridinium
chloride and soya lecithin.

35

- 23 -

9. The formulation of claim 1 containing the following components in the indicated ranges:

5	medicament	0.01-1 wt %
	1,1,1,2 tetrafluoroethane	25 - 99.99 wt %
	excipient	0 - 75 wt %
	surfactant	0 - 3 wt %

10. The formulation of claim 9 containing the following components in the indicated ranges:

10	medicament	0.03 - 0.7 wt%
	1,1,1,2 tetrafluoroethane	50 - 99.97 wt%
	excipient	0 - 50 wt%
	surfactant	0 - 2 wt%

15 11. The formulation of claim 10 containing the following components in the indicated ranges:

20	medicament	0.05 - 0.5 wt%
	1,1,1,2 tetrafluoroethane	50 - 99.95 wt%
	excipient	0 - 50 wt%
	surfactant	0 - 1 wt%

12. The formulation of claim 9 wherein the medicament is a powder having a mean particle size of about 1-5 microns.

25

13. A method for treating mammals comprising administering to said mammals an effective amount the aerosol formulation of claim 1.

14. A method of treating asthma in mammals comprising
30 administering to a mammal in need of such treatment an effective amount of aerosol formulation consisting essentially of:

- 24 -

- A. a medicament selected from the group comprising albuterol, mometasone furoate, beclomethasone dipropionate, and salts and clathrates thereof;
- B. 1,1,1,2 tetrafluoroethane;
- 5 C. optionally an excipient selected from the group consisting of:
- propylene glycol diesters of medium chain fatty acids;
triglyceride esters of medium chain fatty acids;
10 perfluorodimethylcyclobutane;
perfluorocyclobutane;
polyethylene glycol;
menthol;
lauroglycol;
15 diethylglycol monoethylether;
polyglycolized glycerides of medium chain fatty acids;
alcohols;
short chain fatty acids;
20 eucalyptus oil; and combinations thereof;
- D. optionally a surfactant selected from the group consisting of:
- 25 oleic acid;
sorbitan trioleate;
cetyl pyridinium chloride;
soya lecithin;
polyoxyethylene (20) sorbitan monolaurate;
30 polyoxyethylene (20) sorbitan monostearate;
polyoxyethylene (20) sorbitan monooleate;
polyoxyethylene (10) stearyl ether;
polyoxyethylene (2) oleyl ether;
polyethylene-polyoxypropylene-ethylenediamine block
35 copolymers;


- 25 -

polyoxypropylene-polyoxyethylene block copolymers;
castor oil ethoxylate; and combinations thereof; and

- 5 E. optionally one or more additives selected from at least one
of the following classes:
 preservatives;
 buffers;
 antioxidants;
 sweeteners; and
10 taste masking agents.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 92/04618

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 A 61 K 9/72 C 09 K 3/30		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	A 61 K C 07 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0372777 (RIKER LABORATORIES, INC.) 13 June 1990, see the whole document (cited in the application) ---	1-14
X	WO,A,9104011 (RIKER LABORATORIES, INC.) 4 April 1991, see the whole document, in particular page 15, example 2, lines 35-40 (cited in the application) ---	1-14
X	WO,A,9011754 (FISONS PLC) 18 October 1990, see the whole document, in particular page 9, lines 15,16 ---	1-3,9-14
X	WO,A,9007333 (RIKER LABORATORIES, INC.) 12 July 1990, see pages 12-14, examples 4,5 ---	1-3,9-14
P,X	WO,A,9208446 (GLAXO GROUP LTD) 29 May 1992, see pages 5,6, example 1 --- -/-	1,3-6,8-14
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
14-08-1992	04. 09. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE		

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	WO,A,9200107 (GLAXO INC.) 9 January 1992, see the whole document ----	1,4-6,9-14
P,X	WO,A,9200062 (MINNESOTA MINING AND MANUFACTURING CO.) 9 January 1992, see page 1, line 1 - page 13, line 29; claims ----	1,2,4-6,9-14
P,X	WO,A,9200061 (FISONS PLC) 9 January 1992, see page 1, line 1 - page 8, line 2; pages 8-10, examples 1-3,7-9,17,18; claims ----	1-6,9-14
P,X	WO,A,9114422 (MINNESOTA MINING AND MANUFACTURING CO.) 3 October 1991, see page 1, line 1 - page 16, line 10; claims ----	1,4-6,9-14
P,X	WO,A,9111495 (BOEHRINGER INGELHEIM INT. GmbH) 8 August 1991, see the whole document, in particular page 6, examples 3,6 ----	1-6,8-14
P,X	WO,A,9111173 (FISONS PLC) 8 August 1991, see page 1, line 1 - page 9, line 10; pages 9,10, examples 1,3,5,7; claims -----	1-14

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9204618
SA 61183

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 01/09/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0372777	13-06-90	AU-A- 4595689 CA-A- 2004598 EP-A- 0499344 JP-A- 2200627	14-06-90 06-06-90 19-08-92 08-08-90
WO-A- 9104011	04-04-91	AU-A- 6409790 EP-A- 0493437	18-04-91 08-07-92
WO-A- 9011754	18-10-90	CA-A- 2014401 EP-A- 0467916	12-10-90 29-01-92
WO-A- 9007333	12-07-90	EP-A- 0452384	23-10-91
WO-A- 9208446	29-05-92	None	
WO-A- 9200107	09-01-92	AU-A- 8213591 US-A- 5126123	23-01-92 30-06-92
WO-A- 9200062	09-01-92	AU-A- 8050891	23-01-92
WO-A- 9200061	09-01-92	AU-A- 8055691	23-01-92
WO-A- 9114422	03-10-91	AU-A- 7668691 US-A- 5118494	21-10-91 02-06-92
WO-A- 9111495	08-08-91	DE-A- 4003272 AU-A- 7211391	08-08-91 21-08-91
WO-A- 9111173	08-08-91	None	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.